Deconstruction - Reconstruction: Analysis of the Crucial Structural Elements of GluN2B-Selective, Negative Allosteric NMDA Receptor Modulators with 3-Benzazepine Scaffold

被引:4
作者
Ritter, Nadine [1 ,2 ]
Korff, Marvin [2 ,3 ]
Markus, Alexander [3 ]
Schepmann, Dirk [3 ]
Seebohm, Guiscard [1 ,2 ]
Schreiber, Julian A. [1 ]
Wuensch, Bernhard [2 ,3 ]
机构
[1] Univ Hosp Munster, Dept Cardiovasc Med, Inst Genet Heart Dis IfGH, Cellular Electrophysiol & Mol Biol, Munster, Germany
[2] Westfalische Wilhelms Univ Munster, Chem Biol ion channels Chembion, GRK 2515, Munster, Germany
[3] Westfalische Wilhelms Univ Munster, Inst Pharmaceut & Med Chem, Correns Str 48, D-48149 Munster, Germany
关键词
NMDA receptor; GluN2B subunit; Selective GluN2B antagonists; Negative allosteric modulators; Ifenprodil binding site; Deconstruction; Essential structural elements; Reconstruction; Benzoxazolone bioisosteres; Modification of electron density;
D O I
10.33594/000000335
中图分类号
Q2 [细胞生物学];
学科分类号
071009 ; 090102 ;
摘要
Background/Aims: The NMDA receptor plays a key role in the pathogenesis of neurodegenerative disorders including Alzheimer's and Huntington's disease, as well as depression and drug or alcohol dependence. Due to its participation in these pathologies, the development of selective modulators for this ion channel is a promising strategy for rational drug therapy. The prototypical negative allosteric modulator ifenprodil inhibits selectively GluN2B subunit containing NMDA receptors. It was conformationally restricted as 2-methyl-3-(4-phenylbutyl)-2,3,4,5-tetrahydro-1H-3-benzazepine-1,7-diol, which showed high GluN2B affinity and inhibitory activity. For a better understanding of the relevance of the functional groups and structural elements, the substituents of this 3-benzazepine were removed successively (deconstruction). Then, additional structural elements were introduced (reconstruction) with the aim to analyze, which additional modifications were tolerated by the GluN2B receptor. Methods: The GluN2B affinity was recorded in radioligand receptor binding studies with the radioligand [3H]ifenprodil. The activity of the ligands was determined in twoelectrode voltage clamp experiments using Xenopus laevis oocytes transfected with cRNA encoding the GluN1-1a and GluN2B subunits of the NMDA receptor. Docking studies showed the crucial interactions with the NMDA receptor protein. Results: The deconstruction approach showed that removal of the methyl moiety and the phenolic OH moiety in 7-positon resulted in almost the same GluN2B affinity as the parent 3-benzazepine. A considerably reduced GluN2B affinity was found for the 3-benzazepine without further substituents. However, removal of one or both OH moieties led to considerably reduced NMDA receptor inhibition. Introduction of a NO 2 moiety or bioisosteric replacement of the phenol by a benzoxazolone resulted in comparable GluN2B affinity, but almost complete loss of inhibitory activity. An O-atom, a carbonyl moiety or a F-atom in the tetramethylene spacer led to 6-7-fold reduced ion channel inhibition. Conclusion: The results reveal an uncoupling of affinity and activity for the tested 3-benzazepines. Strong inhibition of [3H]ifenprodil binding by a test compound does not necessarily translate into strong inhibition of the ion flux through the NMDA receptor associated ion channel. 3-(4-Phenylbutyl)-2,3,4,5-tetrahydro-1H-3-benzazepine1,7-diol (WMS-1410) shows high GluN2B affinity and strong inhibition of the ion channel. Deconstruction by removal of one or both OH moieties reduced the inhibitory activity proving the importance of the OH groups for ion channel blockade. Reconstruction by introduction of various structural elements into the left benzene ring or into the tetramethylene spacer reduced the NMDA receptor inhibition. It can be concluded that these modifications are not able to translate binding into inhibition. (c) 2021 The Author(s). Published by Cell Physiol Biochem Press GmbH&Co. KG
引用
收藏
页码:1 / 13
页数:13
相关论文
共 6 条
  • [1] Role of the phenolic OH moiety of GluN2B-selective NMDA antagonists with 3-benzazepine scaffold
    Dey, Sougata
    Schepmann, Dirk
    Wuensch, Bernhard
    BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2016, 26 (03) : 889 - 893
  • [2] Mapping the Binding of GluN2B-Selective N-Methyl-D-aspartate Receptor Negative Allosteric Modulators
    Burger, Pieter B.
    Yuan, Hongjie
    Karakas, Erkan
    Geballe, Matthew
    Furukawa, Hiro
    Liotta, Dennis C.
    Snyder, James P.
    Traynelis, Stephen F.
    MOLECULAR PHARMACOLOGY, 2012, 82 (02) : 344 - 359
  • [3] Fluorinated GluN2B Receptor Antagonists with a 3-Benzazepine Scaffold Designed for PET Studies
    Szermerski, Marina
    Boergel, Frederik
    Schepmann, Dirk
    Haider, Ahmed
    Betzel, Thomas
    Ametamey, Simon M.
    Wuensch, Bernhard
    CHEMMEDCHEM, 2018, 13 (10) : 1058 - 1068
  • [4] Deconstruction - reconstruction approach to analyze the essential structural elements of tetrahydro-3-benzazepine-based antagonists of GluN2B subunit containing NMDA receptors
    Dey, Sougata
    Temme, Louisa
    Schreiber, Julian A.
    Schepmann, Dirk
    Frehland, Bastian
    Lehmkuhl, Kirstin
    Strutz-Seebohm, Nathalie
    Seebohm, Guiscard
    Wuensch, Bernhard
    EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, 2017, 138 : 552 - 564
  • [5] Novel GluN2B-Selective NMDA Receptor Negative Allosteric Modulator Possesses Intrinsic Analgesic Properties and Enhances Analgesia of Morphine in a Rodent Tail Flick Pain Model
    Harris, Lynnea D.
    Regan, Michael C.
    Myers, Scott J.
    Nocilla, Kelsey A.
    Akins, Nicholas S.
    Tahirovic, Yesim A.
    Wilson, Lawrence J.
    Dingledine, Ray
    Furukawa, Hiro
    Traynelis, Stephen F.
    Liotta, Dennis C.
    ACS CHEMICAL NEUROSCIENCE, 2023, : 917 - 935
  • [6] Negative allosteric modulators of the GluN2B NMDA receptor with phenylethylamine structure embedded in ring-expanded and ring-contracted scaffolds
    Temme, Louisa
    Bechthold, Elena
    Schreiber, Julian A.
    Gawaskar, Sandeep
    Schepmann, Dirk
    Robaa, Dina
    Sippl, Wolfgang
    Seebohm, Guiscard
    Wuensch, Bernhard
    EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, 2020, 190